Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Tesamorelin 10 mg is a synthetic growth hormone-releasing hormone analog studied for its role in endogenous growth hormone signaling, IGF-1 pathway activation, visceral adiposity models, metabolic regulation, and body composition research.
Tesamorelin is structurally related to human growth hormone-releasing factor and is designed to stimulate GHRH/GRF receptor pathways associated with pulsatile growth hormone release from pituitary somatotroph cells. FDA prescribing information describes tesamorelin as a synthetic human growth hormone-releasing factor analog that binds and stimulates human GRF receptors, supporting endogenous GH release.
In research and clinical literature, tesamorelin has been studied primarily for its effects on visceral adipose tissue, particularly in models of HIV-associated lipodystrophy. Clinical data show that tesamorelin can reduce excess abdominal/visceral fat in that context, while its broader metabolic applications remain research-dependent and should not be overstated.
Research areas commonly associated with Tesamorelin include:
growth hormone-releasing hormone receptor signaling
endogenous GH and IGF-1 axis modulation
visceral adiposity research
body composition models
metabolic health research
lipolysis-associated pathways
endocrine signaling studies
hepatic and cardiometabolic research models
Synthera Labs presents Tesamorelin as part of its endocrine and metabolic research line, supported by global raw material sourcing, analytical documentation review, downstream processing standards, batch traceability, and QR-linked verification.
Product format: Lyophilized peptide
Concentration: 10 mg
Category: Endocrine / Metabolic Research
Peptide system: Tesamorelin
Use: Research use only
Disclaimer: This product is intended for laboratory research purposes only. Not for human consumption, diagnostic use, therapeutic use, or clinical application.
Tesamorelin 10 mg is a synthetic growth hormone-releasing hormone analog studied for its role in endogenous growth hormone signaling, IGF-1 pathway activation, visceral adiposity models, metabolic regulation, and body composition research.
Tesamorelin is structurally related to human growth hormone-releasing factor and is designed to stimulate GHRH/GRF receptor pathways associated with pulsatile growth hormone release from pituitary somatotroph cells. FDA prescribing information describes tesamorelin as a synthetic human growth hormone-releasing factor analog that binds and stimulates human GRF receptors, supporting endogenous GH release.
In research and clinical literature, tesamorelin has been studied primarily for its effects on visceral adipose tissue, particularly in models of HIV-associated lipodystrophy. Clinical data show that tesamorelin can reduce excess abdominal/visceral fat in that context, while its broader metabolic applications remain research-dependent and should not be overstated.
Research areas commonly associated with Tesamorelin include:
growth hormone-releasing hormone receptor signaling
endogenous GH and IGF-1 axis modulation
visceral adiposity research
body composition models
metabolic health research
lipolysis-associated pathways
endocrine signaling studies
hepatic and cardiometabolic research models
Synthera Labs presents Tesamorelin as part of its endocrine and metabolic research line, supported by global raw material sourcing, analytical documentation review, downstream processing standards, batch traceability, and QR-linked verification.
Product format: Lyophilized peptide
Concentration: 10 mg
Category: Endocrine / Metabolic Research
Peptide system: Tesamorelin
Use: Research use only
Disclaimer: This product is intended for laboratory research purposes only. Not for human consumption, diagnostic use, therapeutic use, or clinical application.